BioCryst Pharmaceuticals is a biotechnology company that discovers oral, small-molecule medicines. The company focuses on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the main role in the biological pathway of the disease. The company's drug/drug candidates include: Berotralstat (BCX7353), an oral serine protease inhibitor targeting kallikrein that is being developed as a once-daily oral therapy for the prevention of Hereditary Angioedema; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; and BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.